- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Sionna Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Stifel reiterates Buy on Sionna Therapeutics stock ahead of data | 16 | Investing.com | ||
| 26.05. | Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential | 1 | Investing.com | ||
| 26.05. | Citizens bestätigt Rating für Sionna Therapeutics wegen Potenzials bei Mukoviszidose-Therapie | 1 | Investing.com Deutsch | ||
| 20.05. | Freedom Broker stuft Sionna Therapeutics auf "Halten" herab | 1 | Investing.com Deutsch | ||
| 20.05. | Sionna Therapeutics stock rating cut to Hold at Freedom Broker | 2 | Investing.com | ||
| 18.05. | Stifel raises Sionna Therapeutics price target on NBD1 data confidence | 1 | Investing.com | ||
| 12.05. | Guggenheim reiterates Sionna Therapeutics stock rating at Buy | 1 | Investing.com | ||
| SIONNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.05. | Sionna Therapeutics GAAP EPS of -$0.60 | 1 | Seeking Alpha | ||
| 12.05. | Raymond James reiterates Strong Buy on Sionna stock ahead of summer data | 1 | Investing.com | ||
| 12.05. | Sionna Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | Sionna Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Aktie von Sionna Therapeutics erreicht Rekordhoch bei 46,65 US-Dollar | 4 | Investing.com Deutsch | ||
| 04.05. | Wedbush initiates Sionna Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| 28.04. | Jones Trading raises Sionna Therapeutics price target on trial progress | 2 | Investing.com | ||
| 27.04. | Sionna schließt Rekrutierung für Mukoviszidose-Studie ab | 3 | Investing.com Deutsch | ||
| 27.04. | Sionna completes enrollment in cystic fibrosis drug trial | 1 | Investing.com | ||
| 27.04. | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | 351 | GlobeNewswire (Europe) | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| 02.03. | Sionna Therapeutics GAAP EPS of -$0.46 | 4 | Seeking Alpha | ||
| 02.03. | Guggenheim raises Sionna Therapeutics stock price target to $50 | 1 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,70 | +0,06 % | Milliardenmarkt psychische Gesundheit: Unentdecktes Small-Cap vs. Big-Pharma wie Bayer, Novo Nordisk und BioNTech | ||
| VALNEVA | 2,297 | -0,13 % | Valneva zieht durch: Was hinter dem Kursanstieg wirklich steckt - Meine Einschätzung für die neue Börsenwoche | ||
| AMGEN | 293,55 | +0,53 % | MariTide-Ausblick: Mizuho hebt Amgen-Kursziel auf 303 US-Dollar an | ||
| NOVAVAX | 7,910 | -0,50 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 170,64 | -0,23 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| VIVOSIM LABS | 1,135 | +3,18 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,700 | +0,95 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 13,520 | +1,20 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 43,870 | +0,49 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| VIVORYON THERAPEUTICS | 1,095 | +0,92 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,006 | +2,35 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,570 | -1,49 % | BioMarin legt überzeugende Dreijahresdaten für VOXZOGO bei Hypochondroplasie vor | ||
| EXELIXIS | 45,980 | +0,17 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,320 | +0,52 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG |
SIONNA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,11 % bei einem Aktienkurs von 37,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIONNA THERAPEUTICS INC finden Sie auf Wallstreet Online.